<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1029">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147753</url>
  </required_header>
  <id_info>
    <org_study_id>7337_20042021</org_study_id>
    <nct_id>NCT05147753</nct_id>
  </id_info>
  <brief_title>Moxonidine Effects on Neuropeptide Y</brief_title>
  <official_title>Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild&#xD;
      or moderate hypertension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate&#xD;
      hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg,&#xD;
      Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg,&#xD;
      diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12&#xD;
      weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2010</start_date>
  <completion_date type="Actual">June 30, 2014</completion_date>
  <primary_completion_date type="Actual">June 30, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum Neuropeptide Y levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6 mg moxonidine daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine</intervention_name>
    <description>0.6 mg moxonidine daily</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  treatment-naïve subjects with mild or moderate hypertension according to Joint&#xD;
             National Committee 7 and European Society Hypertension / European Society Cardiology&#xD;
             2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99&#xD;
             mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require&#xD;
             monotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age beyond 25-75 years,&#xD;
&#xD;
          -  not taking currently anti-hypertensive medication&#xD;
&#xD;
          -  not taking anti-diabetic or lipid lowering medication and other diseases or conditions&#xD;
             that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y&#xD;
             levels, including anemia, fever, stage III hypertension, coronary artery disease,&#xD;
             recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary&#xD;
             hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related&#xD;
             endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression&#xD;
             or other psychiatric illnesses, such as schizophrenia,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni Karlafti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Prof. Triantafyllos Didangelos</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine-Diabetology</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>obesity</keyword>
  <keyword>Neuropeptide Y</keyword>
  <keyword>moxonidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

